RDNT
RadNet Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, and among others.
RadNet, Inc. (RDNT) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Value (C-). The rating has held at C+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C- (2.1) | C+ (2.6) | C (2.5) | B (3.4) | C+ (2.6) | C+ (2.7) |
| 2026-11-07 | D+ (1.8) | C+ (2.5) | C (2.5) | B- (3.1) | C+ (2.7) | C+ (2.5) |
| 2026-10-31 | C- (2.0) | C (2.5) | C (2.5) | B (3.2) | C+ (2.7) | C+ (2.6) |
| 2026-10-24 | C- (2.1) | C+ (2.5) | C (2.5) | B (3.2) | C+ (2.6) | C+ (2.6) |
| 2026-10-17 | C (2.2) | C+ (2.5) | C (2.5) | B (3.4) | C+ (2.6) | C+ (2.6) |